Breaking News

Early Stage Vaccine Targets Hallmarks of Alzheimer's Disease

November 22, 2021 • 11:00 am CST
(Precision Vaccinations)

The California-based Institute for Molecular Medicine (IMM) today announced that it had been awarded an additional $3 million to the previously awarded $4.7 million grant from the NIH's National Institutes of Aging.

The new award will support the manufacturing of a first-of-its-kind clinical cGMP grade dual vaccine, Duvax, that targets both pathological hallmarks of Alzheimer's disease (AD), amyloid-beta plaques (Aβ) and neurofibrillary tangles (tau). 

Current clinical data on AD biomarkers found in the brain and cerebrospinal fluid demonstrate that Aβ accumulation can precede tau pathology and cognitive decline by sometimes more than a decade.

The IND-enabling safety/toxicology studies with a cGMP grade recombinant protein vaccine targeting tau, AV-1980R, has been recently completed using the NIH funding and is currently on track for a Phase 1 clinical trial to evaluate its safety, tolerability, and immunogenicity.

The additional funding is being used to manufacture a clinical-grade recombinant protein vaccine targeting pathological Aβ, AV-1959R, and test its safety in animal models of AD.

This vaccine will be tested in 2022 in a clinical setting.

Notably, the additional funding will also be used to manufacture Duvax for use in phase 1 trials that are expected to be completed in 2023.

"Supported by strong pre-clinical data, we believe that Duvax will induce high titers of anti-Aβ and anti-tau antibodies that could inhibit or reduce the accumulation of both pathological molecules and halt or at least delay downstream pathological processes, such as inflammation and neurodegeneration, which would otherwise lead to an irreversible onset of AD in asymptomatic people at risk," said Michael Agadjanyan, Vice President of IMM and Head of Immunology, in a press release.

All vaccines are based on IMM's proprietary MultiTEP platform technology, recently licensed to its commercial entity, Nuravax.

The Institute for Molecular Medicine is a non-profit research organization established in Huntington Beach, Calif., during 1996 with the goal of understanding, preventing, and curing chronic diseases, including neurodegenerative disorders.

Medical Review by